Article info
PDFInflammatory bowel disease
CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial
- Correspondence to:
Dr W J Sandborn
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA; sandborn.williammayo.edu
Citation
CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial
Publication history
- Received March 16, 2004
- Accepted March 31, 2004
- First published September 10, 2004.
Online issue publication
April 18, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2004 by Gut